Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.

Andrea BotticelliPamela VernocchiFederico MariniAndrea QuagliarielloBruna CerbelliSofia ReddelFederica Del ChiericoFrancesca Di PietroRaffaele GiustiAlberta TomassiniOttavia GiampaoliAlfredo MiccheliIlaria Grazia ZizzariMarianna NutiLorenza PutignaniPaolo Marchetti

Published in: Journal of translational medicine (2020)

Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked "indicators" of early progressor and long responder patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
small cell lung cancer
prognostic factors
machine learning
single cell
artificial intelligence
big data